What is the dosing for zynteglo?

Zynteglo Dosing Basics

Zynteglo (betibeglogene autotemcel) is a one-time gene therapy infusion for beta-thalassemia patients needing regular transfusions. The dose is 1.8 × 10^6 CD34+ cells per kg of patient body weight, administered as a single intravenous infusion after myeloablative conditioning.[1][2]

How Dosing Is Calculated and Prepared

Dose calculation uses the patient's actual body weight before starting conditioning chemotherapy. The product arrives autologous (patient-derived), cryopreserved, and ready for thaw and infusion—no further dilution needed. Total viable CD34+ cells must meet or exceed the prescribed amount; potency is verified via release testing.[1][2]

Conditioning Regimen Before Infusion

Patients undergo myeloablative conditioning (e.g., busulfan) 2-3 days prior to wipe out bone marrow and create space. Conditioning starts after stable health confirmation and ends before infusion day. Full details follow institutional protocols.[1][2]

What Happens During and After Infusion

Infusion occurs over 30-60 minutes via central line in a controlled setting. Patients stay hospitalized for at least four weeks post-infusion for monitoring engraftment and complications like infections or bleeding. No repeat doses are given.[1][2]

Patient Selection and Weight Considerations

Approved for ages 12+ (FDA) or 5+ (EU) with transfusion-dependent beta-thalassemia and specific genotypes. Use ideal body weight if obese; consult prescribing info for pediatric adjustments. Not for those with active infections or certain HLA matches.[1][2]

[1]: Zynteglo Prescribing Information (FDA)
[2]: Zynteglo EMA Product Information